Here’s What the Street is Saying About Amgen Inc. (AMGN)

Core Insights - Amgen Inc. (NASDAQ:AMGN) is recognized as a strong immunotherapy stock by hedge funds, but has recently been downgraded to Hold from Buy by Freedom Capital, with a revised price target of $375 from $360, citing fair value and ongoing exclusivity challenges [1][2]. Financial Performance - For fiscal Q4, Amgen reported total revenues of $9.9 billion, reflecting a 9% increase year-over-year, with product sales growing by 7% driven by a 10% increase in volume [3]. - The full-year revenue for 2025 reached $36.8 billion, marking a 10% increase compared to the previous year [3]. Product Developments - The European Commission approved UPLIZNA® as an add-on treatment for adults with generalized myasthenia gravis, providing a new targeted treatment option that may enhance long-term disease control [2].